Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.67 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.67 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962597 | 0.90 | GID4 (0.73) | SPHK2SPHK1GID4MAOAMAOB | |
| Hydrochloric Acid SCHEMBL9127887 | 0.89 | GID4 (0.71) | SPHK2SPHK1GID4MAOAMAOB | |
| SCHEMBL9903566 | 0.87 | HDAC1 (0.56) | SPHK2SPHK1GID4 | |
| SCHEMBL964244 | 0.85 | SPHK2 (0.67) | SPHK2SPHK1NR4A2MAOAMAOB | |
| SCHEMBL964604 | 0.83 | SPHK2 (0.65) | SPHK2SPHK1NR4A2MAOAMAOB | |
| SCHEMBL69355 | 0.81 | MAOB (0.60) | SPHK2SPHK1GID4MAOAMAOB | |
| SCHEMBL966003 | 0.80 | MAOB (0.62) | NR4A2MAOAMAOBPKM | |
| SCHEMBL17894461 | 0.80 | NPC1 (0.55) | GID4NR4A2MAOAMAOBNPC1 | |
| SCHEMBL7396470 | 0.79 | GID4 (0.78) | SPHK2SPHK1GID4NR4A2MAOA | |
| SCHEMBL9117138 | 0.79 | BCHE (0.52) | SPHK2SPHK1GID4NR4A2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | claimed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | claimed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | claimed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | claimed |
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | disclosed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | disclosed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GABBR1, GABBR2, GABRA5 | SPHK2 4354/4885SPHK1 4298/4885GID4 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.